Meeting
2014 Genitourinary Cancers Symposium
Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer.
Authors
Bertrand Tombal
Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Bertrand Tombal , Jan-Erik Damber , Anders Malmberg , Bo-Eric Persson , Laurence Klotz , Peter Iversen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 86)
DOI
10.1200/jco.2014.32.4_suppl.86
Abstract #
86
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Influence of cardiovascular (CV) comorbidities on the selection of hormone deprivation therapy (HDT) in the treatment of metastatic prostate cancer (mPCa).
First Author: Jan Lehmann
Poster
2018 Genitourinary Cancers Symposium
Cardiovascular comorbidities in German prostate cancer patients under androgen deprivation therapy: Results from a retrospective analysis of patient data in urological outpatient centers.
First Author: Andreas Eisenhardt
Poster
2016 Genitourinary Cancers Symposium
Incidence of testosterone escape with LHRH agonists in patients receiving radiotherapy for prostate cancer.
First Author: Derek R Wilke
Poster
2023 ASCO Annual Meeting
Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT.
First Author: Ye Yuan